Search is Powered by Google
Pharma Industry / Biotech Industry News

House Committee Leaders Warn Pharmaceutical Companies To End Use Of 'Misleading' Advertisements

Main Category: Pharma Industry / Biotech Industry
Also Included In: Public Health
Article Date: 22 May 2008 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:3 stars

3 (2 votes)

Health Professional:5 stars

5 (1 votes)

Article Opinions: 0 posts

House Energy and Commerce Committee Chair John Dingell (D-Mich.) and Oversight and Investigations Subcommittee Chair Bart Stupak (D-Mich.) in a recent letter warned four pharmaceutical companies to end the use of "misleading and deceptive" direct-to-consumer advertisements for medications, CQ HealthBeat reports. The lawmakers sent the letter to Johnson & Johnson, Merck, Pfizer and Schering-Plough, as well as the Pharmaceutical Research and Manufacturers of America.

In the letter, the lawmakers asked the pharmaceutical companies to end the use of health care professionals in DTC ads and to wait for two years before they air such ads for new medications, among other requests. According to Dingell, the lawmakers sent the letter after pharmaceutical industry representatives failed to assure them of their efforts to reduce adverse effects of DTC ads at a May 8 hearing of the subcommittee.

Dingell in a statement said, "Marketing department leaders have failed to commit to reducing misleading and deceptive ads, so we're now asking the CEOs to make this agreement." Stupak said, "We intend to make certain that drug companies market their product properly in order to protect American consumers from manipulative commercials designed to mislead and deceive for profit."

Ken Johnson, senior vice president of PhRMA, said that the group will maintain "honest and open dialogue" with lawmakers over DTC ads, which he said "inform patients potentially suffering from disease" and help the "entire health care system in the U.S. by encouraging patients to seek medical attention that may help them manage their conditions and avoid unneeded hospital stays or surgeries" (Cooley, CQ HealthBeat, 5/20).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
U.S. FDA Approves Requip® XL™, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
15 Jun 2008
GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease...


When Your Cycle Becomes a Major Headache
When Your Cycle Becomes a Major Headache

Cathy's gets as many as 12 to 15 headaches a month and they are all associated with her menstrual cycle. Migraines like hers tend to last longer and be more severe than other migraines. Figuring out what was triggering her headaches helped Cathy and her doctor come up with a successful treatment plan.

more videos are available in our health videos section.